Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity-Reference-Cited by-同舟云学术

Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity

Published:2020-11-18 Issue:2 Volume:35 Page:381-397
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Inoue Kazunori,Matsui Isao,Hamano Takayuki,Okuda Keiji,Tsukamoto Yasumasa,Matsumoto Ayumi,Shimada Karin,Yasuda Seiichi,Katsuma Yusuke,Takabatake Yoshitsugu,Tanaka Masaru,Tanaka Noriko,Mano Toshiaki,Minamino Tetsuo,Sakata Yasushi,Isaka Yoshitaka

Funder

Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology

The Kidney Foundation, Japan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10557-020-07111-9.pdf

Reference53 articles.

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

2. Das M, Aronow WS, McClung JA, Belkin RN. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev. 2006;14(1):14–7.